1. Home
  2. MEIP vs ONMD Comparison

MEIP vs ONMD Comparison

Compare MEIP & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • ONMD
  • Stock Information
  • Founded
  • MEIP 2000
  • ONMD 2006
  • Country
  • MEIP United States
  • ONMD United States
  • Employees
  • MEIP N/A
  • ONMD N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • ONMD
  • Sector
  • MEIP Health Care
  • ONMD
  • Exchange
  • MEIP Nasdaq
  • ONMD Nasdaq
  • Market Cap
  • MEIP 13.3M
  • ONMD 12.8M
  • IPO Year
  • MEIP 2003
  • ONMD N/A
  • Fundamental
  • Price
  • MEIP $6.60
  • ONMD $0.54
  • Analyst Decision
  • MEIP Hold
  • ONMD
  • Analyst Count
  • MEIP 1
  • ONMD 0
  • Target Price
  • MEIP N/A
  • ONMD N/A
  • AVG Volume (30 Days)
  • MEIP 2.8M
  • ONMD 357.1K
  • Earning Date
  • MEIP 09-18-2025
  • ONMD 05-14-2025
  • Dividend Yield
  • MEIP N/A
  • ONMD N/A
  • EPS Growth
  • MEIP N/A
  • ONMD N/A
  • EPS
  • MEIP N/A
  • ONMD N/A
  • Revenue
  • MEIP N/A
  • ONMD $532,000.00
  • Revenue This Year
  • MEIP N/A
  • ONMD N/A
  • Revenue Next Year
  • MEIP N/A
  • ONMD N/A
  • P/E Ratio
  • MEIP N/A
  • ONMD N/A
  • Revenue Growth
  • MEIP 33.76
  • ONMD N/A
  • 52 Week Low
  • MEIP $1.46
  • ONMD $0.30
  • 52 Week High
  • MEIP $9.00
  • ONMD $1.60
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 81.52
  • ONMD 50.87
  • Support Level
  • MEIP $5.75
  • ONMD $0.50
  • Resistance Level
  • MEIP $9.00
  • ONMD $0.57
  • Average True Range (ATR)
  • MEIP 0.85
  • ONMD 0.05
  • MACD
  • MEIP 0.39
  • ONMD -0.01
  • Stochastic Oscillator
  • MEIP 62.50
  • ONMD 27.13

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About ONMD OneMedNet Corp

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its innovative solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols and paves the way for Real World Evidence.

Share on Social Networks: